Do Children Taking SGAs Get Metabolic Monitoring?
Careful monitoring of adverse effects of psychotropic drugs in general and second-generation antipsychotics in particular falls below recommended standards for children and adolescents.
A New Treatment for Parkinson Disease Psychosis
In a placebo-controlled study of patients with Parkinson disease and psychosis, the 5-HT-2A receptor inverse agonist pimavanserin improved psychotic symptoms and did not worsen motor signs.
Ramelteon (Rozerem) to Prevent Delirium?
Preliminary results from using the melatonin-receptor agonist ramelteon (Rozerem) in hospitalized patients to prevent delirium are encouraging.
Starting Dose of Eszopiclone Lowered to Avoid Next-Day Impairment; Study Examines Determinants of Antipsychotic Treatment Response
Anxiolytics, Hypnotics, and Mortality Risk
In a retrospective cohort study, a significant association was found between the use of anxiolytic and hypnotic drugs and an increased risk of death.
n May, the US FDA issued a warning that the sleep aid eszopiclone (Lunesta and others) can cause next-day impairment and lowered the recommended starting dose from 3 mg at bedtime to 1 mg (US Food and Drug Administration. Safety Announcement. Available at: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM397277.pdf.…